China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study for its oral TYK2 inhibitor D-2570 in psoriasis at the American Academy of Dermatology Annual Meeting (AAD). The data demonstrated significant improvements in patients treated with D-2570 compared to the placebo group.
Study Results
After 12 weeks of treatment, 90.0%, 85.4%, and 85.0% of patients in the 18mg (low dose), 27mg (medium dose), and 36mg (high dose) groups of D-2570 achieved a 75% reduction in the Psoriasis Area and Severity Index (PASI), markedly better than the placebo group (12.5%, P<0.001), thus reaching the primary endpoint.
Additional Efficacy Data
D-2570 also showed outstanding response rates in PASI90 and PASI100. The PASI90 response rates were 75.0%, 70.7%, and 77.5% in the low, medium, and high dose groups, respectively. PASI100 response rates were 40.0%, 39.0%, and 50.0%, all significantly higher than the placebo group (5.0% and 2.5%, P<0.001).
Implications and Future Steps
These results highlight the potential of D-2570 as an effective oral treatment option for psoriasis patients. InventisBio plans to continue advancing the development of D-2570, with further clinical trials expected to explore its efficacy and safety in larger patient populations.-Fineline Info & Tech
Leave a Reply